- Home
- MEIP vs EVAX Comparison
MEIP vs EVAX Comparison
Compare MEIP & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MEIP
- EVAX
- Stock Information
- Founded
- MEIP 2000
- EVAX 2008
- Country
- MEIP United States
- EVAX Denmark
- Employees
- MEIP N/A
- EVAX N/A
- Industry
- MEIP Biotechnology: Pharmaceutical Preparations
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MEIP Health Care
- EVAX Health Care
- Exchange
- MEIP Nasdaq
- EVAX Nasdaq
- Market Cap
- MEIP 13.3M
- EVAX 10.8M
- IPO Year
- MEIP 2003
- EVAX 2021
- Fundamental
- Price
- MEIP $2.80
- EVAX $2.54
- Analyst Decision
- MEIP Hold
- EVAX Strong Buy
- Analyst Count
- MEIP 1
- EVAX 2
- Target Price
- MEIP N/A
- EVAX $10.00
- AVG Volume (30 Days)
- MEIP 13.3K
- EVAX 125.9K
- Earning Date
- MEIP 05-13-2025
- EVAX 08-13-2025
- Dividend Yield
- MEIP N/A
- EVAX N/A
- EPS Growth
- MEIP N/A
- EVAX N/A
- EPS
- MEIP N/A
- EVAX N/A
- Revenue
- MEIP N/A
- EVAX $3,293,000.00
- Revenue This Year
- MEIP N/A
- EVAX N/A
- Revenue Next Year
- MEIP N/A
- EVAX N/A
- P/E Ratio
- MEIP N/A
- EVAX N/A
- Revenue Growth
- MEIP 33.76
- EVAX 2555.64
- 52 Week Low
- MEIP $1.46
- EVAX $1.20
- 52 Week High
- MEIP $4.10
- EVAX $17.75
- Technical
- Relative Strength Index (RSI)
- MEIP 78.43
- EVAX 55.40
- Support Level
- MEIP $2.21
- EVAX $2.07
- Resistance Level
- MEIP $2.95
- EVAX $2.95
- Average True Range (ATR)
- MEIP 0.15
- EVAX 0.30
- MACD
- MEIP 0.05
- EVAX -0.05
- Stochastic Oscillator
- MEIP 81.48
- EVAX 45.86
About MEIP MEI Pharma Inc.
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.
About EVAX Evaxion Biotech
Evaxion AS is in the field of oncology. It used the AI-Immunology platform.